- Home
- CEV vs SCLX Comparison
CEV vs SCLX Comparison
Compare CEV & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- SCLX
- Stock Information
- Founded
- CEV 1999
- SCLX 2011
- Country
- CEV United States
- SCLX United States
- Employees
- CEV N/A
- SCLX N/A
- Industry
- CEV Finance/Investors Services
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- SCLX Health Care
- Exchange
- CEV Nasdaq
- SCLX Nasdaq
- Market Cap
- CEV 75.9M
- SCLX 81.7M
- IPO Year
- CEV N/A
- SCLX N/A
- Fundamental
- Price
- CEV $10.40
- SCLX $0.55
- Analyst Decision
- CEV
- SCLX Strong Buy
- Analyst Count
- CEV 0
- SCLX 3
- Target Price
- CEV N/A
- SCLX $11.33
- AVG Volume (30 Days)
- CEV 19.6K
- SCLX 184.3K
- Earning Date
- CEV 01-01-0001
- SCLX 12-03-2024
- Dividend Yield
- CEV 4.23%
- SCLX N/A
- EPS Growth
- CEV N/A
- SCLX N/A
- EPS
- CEV 0.36
- SCLX N/A
- Revenue
- CEV N/A
- SCLX $50,833,000.00
- Revenue This Year
- CEV N/A
- SCLX $32.77
- Revenue Next Year
- CEV N/A
- SCLX $50.71
- P/E Ratio
- CEV $29.36
- SCLX N/A
- Revenue Growth
- CEV N/A
- SCLX 9.41
- 52 Week Low
- CEV $8.83
- SCLX $0.54
- 52 Week High
- CEV $10.91
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- CEV 39.01
- SCLX 28.28
- Support Level
- CEV $10.36
- SCLX $0.54
- Resistance Level
- CEV $10.44
- SCLX $0.74
- Average True Range (ATR)
- CEV 0.08
- SCLX 0.11
- MACD
- CEV 0.00
- SCLX -0.03
- Stochastic Oscillator
- CEV 18.18
- SCLX 2.24
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.